Literature DB >> 15593324

Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication.

Mikelle D Bassett1, Scott M Schuetze, Christine Disteche, Thomas H Norwood, Karen Swisshelm, Xiaoqin Chen, James Bruckner, Ernest U Conrad, Brian P Rubin.   

Abstract

BACKGROUND: Intramuscular lipomas and atypical lipomatous tumors (ALT) are common deep-seated lipomatous tumors of the chest wall and extremities. Distinguishing between these two entities can be difficult based on histologic analysis alone. However, the cytogenetic profiles of ALT and intramuscular lipomas are distinct. Correct classification is important, because aggressive local disease recurrence occurs more frequently in patients with ALT than in patients with intramuscular lipoma. The authors examined their single institutional experience and correlated their classification with clinical features and outcome.
METHODS: In the current study, 106 patients with deep-seated, well differentiated adipose tumors of the chest wall and extremities were classified as having ALT or intramuscular lipoma using a combined approach of histology and cytogenetics, if available. The classification was correlated with clinicopathologic features and follow-up data.
RESULTS: Fifty-five patients were classified as having intramuscular lipoma and 51 were classified as having ALT. Classification did not correlate with age and gender (P = 0.28 and P = 0.96, respectively). Intramuscular lipomas were smaller than ALTs (P < 0.0001), but there was significant overlap between the 2 groups. ALT occurred preferentially in the lower extremity (P < 0.0009). Four percent of patients with intramuscular lipomas and 27% of patients with ALTs developed local disease recurrence (P = 0.0006). Disease recurrence did not correlate with patient age at diagnosis, patient gender, tumor size, and tumor location (P = 0.45, P = 0.26, P = 0.49, and P = 0.28, respectively). Within the subset of patients with ALTs, disease recurrence did not correlate with patient age at diagnosis, patient gender, or tumor location (P = 0.38, P = 0.54, and P = 0.86, respectively).
CONCLUSIONS: Classification of deep-seated, well differentiated lipomatous tumors of the extremities and chest wall using a combined approach of histology and cytogenetics correlated well with biologic behavior/disease recurrence. This combined approach is advocated to better stratify patients for treatment purposes and follow-up. (c) 2004 American Cancer Society.

Entities:  

Mesh:

Year:  2005        PMID: 15593324     DOI: 10.1002/cncr.20779

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Low Recurrence Rate and Risk of Distant Metastases following Marginal Surgery of Intramuscular Lipoma and Atypical Lipomatous Tumors of the Extremities and Trunk Wall.

Authors:  Benjamin Presman; Sune Frederik Jauffred; Maj Raundrup Kornø; Michael Mørk Petersen
Journal:  Med Princ Pract       Date:  2019-09-25       Impact factor: 1.927

2.  A clinical review of 11 cases of large-sized well-differentiated liposarcomas.

Authors:  Camilla Arvinius; Elías Torrecilla; Joaquín Beano-Collado; Javier García-Coiradas; Roberto García-Maroto; María Puerto-Vázquez; Juan Luis Cebrián-Parra
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-05-23

3.  Intramuscular Lipoma within a Free Myocutaneous Flap: Systematic Review and Management.

Authors:  Elizabeth M Kenny; Francesco M Egro; Tahsin Oğuz Acartürk
Journal:  J Hand Microsurg       Date:  2018-03-20

4.  The General Surgeon's quandary: atypical lipomatous tumor vs lipoma, who needs a surgical oncologist?

Authors:  Sarah B Fisher; Katherine J Baxter; Charles A Staley; Kevin E Fisher; David K Monson; Douglas R Murray; Shervin V Oskouei; Sharon W Weiss; David A Kooby; Shishir K Maithel; Keith A Delman
Journal:  J Am Coll Surg       Date:  2013-09-25       Impact factor: 6.113

5.  Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.

Authors:  Adrien Daigeler; Daigeler Adrien; Ludger Klein-Hitpass; Klein-Hitpass Ludger; Ingo Stricker; Stricker Ingo; Oliver Müller; Müller Oliver; Cornelius Kuhnen; Kuhnen Cornelius; Ansgar Michael Chromik; Chromik Ansgar Michael; Lars Steinstraesser; Steinstraesser Lars; Ole Goertz; Goertz Ole; Hans-Ulrich Steinau; Steinau Hans-Ulrich; Marcus Lehnhardt; Lehnhardt Marcus
Journal:  Langenbecks Arch Surg       Date:  2009-01-22       Impact factor: 3.445

6.  Surgical resection of massive liposarcomas at the extremities: a 10-year experience in a referral musculoskeletal sarcoma unit.

Authors:  Bárbara Ortiz-Ibáñez; José V Amaya; Francisco Baixauli; Manuel Angulo; Empar Mayordomo-Aranda; Carlos Barrios
Journal:  World J Surg Oncol       Date:  2015-06-25       Impact factor: 2.754

7.  Differentiation of lipoma and atypical lipomatous tumor by a scoring system: implication of increased vascularity on pathogenesis of liposarcoma.

Authors:  Satoshi Nagano; Masahiro Yokouchi; Takao Setoguchi; Yasuhiro Ishidou; Hiromi Sasaki; Hirofumi Shimada; Setsuro Komiya
Journal:  BMC Musculoskelet Disord       Date:  2015-02-22       Impact factor: 2.362

8.  Expression levels of HMGA2 in adipocytic tumors correlate with morphologic and cytogenetic subgroups.

Authors:  Hammurabi Bartuma; Ioannis Panagopoulos; Anna Collin; Domenico Trombetta; Henryk A Domanski; Nils Mandahl; Fredrik Mertens
Journal:  Mol Cancer       Date:  2009-06-09       Impact factor: 27.401

9.  The use of radiation therapy in the management of selected patients with atypical lipomas.

Authors:  Josephine Kang; Maikel Botros; Saveli Goldberg; Christine Giraud; G Petur Nielsen; Yen-Lin Chen; Kevin Raskin; Joseph Schwab; Sam S Yoon; Francis J Hornicek; Thomas F Delaney
Journal:  Sarcoma       Date:  2013-01-15

10.  Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures.

Authors:  Adrien Daigeler; Ludger Klein-Hitpass; Michael Ansgar Chromik; Oliver Müller; Jörg Hauser; Heinz-Herbert Homann; Hans-Ulrich Steinau; Marcus Lehnhardt
Journal:  BMC Cancer       Date:  2008-10-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.